The Pharma Data

JUNE 9, 2025

A Game-Changing Growth Hormone Therapy Lonapegsomatropin is a long-acting recombinant human growth hormone (rhGH) therapy designed to be administered once weekly. Localized commercial production is anticipated to begin by 2028, following the completion of the technology transfer and necessary scale-up processes.

Therapies 40

Therapies Pharmaceuticals Production Treatment 40

The Pharma Data

JULY 2, 2025

Gilead’s HIV Business: Already a Powerhouse Gilead has long been a dominant player in the HIV treatment and prevention market. billion—coming from Biktarvy, a once-daily triple-combination therapy for people living with HIV. Descovy, another key product used for both treatment and PrEP, added $2.1

Marketing 52

Marketing Treatment Therapies Compliance 52

DrugBank

SEPTEMBER 26, 2024

This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles. billion by 2028. One key challenge is the development of biosimilars for complex biologics, such as monoclonal antibodies used in cancer treatment and gene therapies.

Biosimilars 98

Biosimilars Clinical Trials Marketing Production 98

Alta Sciences

AUGUST 29, 2024

Listen or read Issue 33 of The Altascientist on altasciences.com , or wherever you listen to podcasts: GROWING NEEDS FOR CNS THERAPY SOLUTIONS The different parts of the nervous system, including the brain and spinal cord and the peripheral nervous system, are important drug targets for many serious diseases affecting human health.

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

The Pharma Data

NOVEMBER 8, 2020

R&D pipeline continues to drive future value through innovation and differentiated therapies including expected upcoming approval of Tirbanibulin. All Almirall’s production sites continue to operate at full capacity in order to be able to ensure the supply of medicines to all patients requiring treatment.

Licensing 52

Licensing Licensing Marketing Production 52

Agency IQ

AUGUST 16, 2024

Many commenters took issue with the guidance’s statement that, “The contribution of the psychotherapy component to any efficacy observed with psychedelic treatment has not been characterized. In the clinical studies, this consisted of a four-month course of treatment with three doses of MDMA administered in supervised therapy sessions.

FDA 40

FDA Trials Therapies Regulations 40

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. Certain IVDs will be treated differently; companion diagnostics used with drug therapies would have to include the international non-proprietary name (INN) of the medicine the test is used with. There were myriad reasons for the extension.

Regulations 40

Regulations International Government Production 40